Alexandre Abizaid

Showing 1-20 of 42 articles

Coronary interventions

Five-year safety and performance data of a novel third-generation novolimus-eluting bioresorbable scaffold in single de novo lesions

Verheye S, Costa R, Schofer J, Ormiston J, Maeng M, Dudek D, Skurk C, Botelho R, Costa J, Chamié D, Abizaid An, Boersma E, Abizaid A

October 18, 2019 | 10.4244/EIJ-D-18-00292

Three-year clinical and two-year multimodality imaging outcomes of a thin-strut sirolimus-eluting bioresorbable vascular scaffold: MeRes-1 trial

Seth A, Onuma Y, Chandra P, Bahl V, Manjunath C, Mahajan A, Kumar V, Goel P, Wander G, Kaul U, Ajit Kumar V, Abizaid A, Serruys P

September 20, 2019 | 10.4244/EIJ-D-19-00324

Predictors of long-term adverse events after Absorb bioresorbable vascular scaffold implantation: a 1,933-patient pooled analysis from international registries

Caixeta A, Campos C, Felix C, Chieffo A, Capranzano P, Kawamoto H, Tamburino C, Diletti R, Costa Jr J, Onuma Y, van Geuns R, Bartorelli A, Colombo A, Tamburino C, Serruys P, Abizaid A

September 20, 2019 | 10.4244/EIJ-D-16-00796

Coronary interventions

Randomised evaluation of a novel biodegradable polymer-based sirolimus-eluting stent in ST-segment elevation myocardial infarction: the MASTER study

Valdés Chávarri M, Kedev S, Neskovic A, de la Tassa CM, Zivkovic M, Nouche RT, Vázquez-González N, Bartorelli A, Antoniucci D, Tamburino C, Colombo A, Abizaid A, McFadden E, Garcia-Garcia H, Milasinovic D, Stankovic G

April 5, 2019 | 10.4244/EIJ-D-17-01087

Coronary interventions

Intravascular ultrasound findings of the Fantom sirolimus-eluting bioresorbable scaffold at six- and nine-month follow-up: the FANTOM II study

van Zandvoort L, Dudek D, Weber-Albers J, Abizaid A, Christiansen EH, Muller D, Kochman J, Kołtowski Ł, Lassen JF, Wojdyla R, Wykrzykowska J, Onuma Y, Daemen J

December 7, 2018 | 10.4244/EIJ-D-18-00491

Coronary interventions

Randomised comparison of a biodegradable polymer ultra-thin sirolimus-eluting stent versus a durable polymer everolimus-eluting stent in patients with de novo native coronary artery lesions: the meriT-V trial

Abizaid A, Kedev S, Kedhi E, Talwar S, Erglis A, Hlinomaz O, Masotti M, Fath-Ordoubadi F, Lemos P, Milewski K, Botelho R, Costa R, Bangalore S

December 7, 2018 | 10.4244/EIJ-D-18-00762

Coronary interventions

Relation between bioresorbable scaffold sizing using QCA-Dmax and long-term clinical outcomes in 1,232 patients from three study cohorts (ABSORB Cohort B, ABSORB EXTEND, and ABSORB II)

Katagiri Y, Onuma Y, Asano T, Chichareon P, Collet C, Miyazaki Y, Piek J, Wykrzykowska J, Abizaid A, Ormiston J, Chevalier B, Serruys P

October 12, 2018 | 10.4244/EIJ-D-18-00301

Two-year outcomes of high bleeding risk patients with acute coronary syndrome after Biolimus A9 polymer-free drug-coated stents: a LEADERS FREE substudy

Jensen C, Naber C, Urban P, Ong PJ, Valdés Chávarri M, Abizaid A, Pocock S, Fabbiocchi F, Dubois C, Copt S, Stoll H-P, Morice M

March 20, 2018 | 10.4244/EIJ-D-17-00720

Transcatheter aortic valve implantation for mixed versus pure stenotic aortic valve disease

Abdelghani M, Cavalcante R, Miyazaki Y, de Winter R, Tijssen J, Sarmento-Leite R, Mangione J, Abizaid A, Lemos P, Serruys P, de Brito Jr F

November 20, 2017 | 10.4244/EIJ-D-17-00328

Assessment of long-term mortality in patients with complex coronary artery disease undergoing percutaneous intervention: comparison of multiple anatomical and clinical prognostic risk scores

Janella B, Campos C, Caixeta A, Almeida B, Sandoli Brito Jr F, Abizaid A, Perin M

November 20, 2017 | 10.4244/EIJ-D-16-00659

Transfemoral TAVI using the self-expanding ACURATE neo prosthesis: one-year outcomes of the multicentre “CE-approval cohort”

Möllmann H, Walther T, Siqueira D, Diemert P, Treede H, Grube E, Nickenig G, Baldus S, Rudolph T, Kuratani T, Sawa Y, Kempfert J, Kim W, Abizaid A

October 11, 2017 | 10.4244/EIJ-D-17-00187

Coronary interventions

Sustained safety and clinical performance of a drug-eluting absorbable metal scaffold up to 24 months: pooled outcomes of BIOSOLVE-II and BIOSOLVE-III

Haude M, Ince H, Kische S, Abizaid A, Toelg R, Lemos P, Van Mieghem N, Verheye S, von Birgelen C, Christiansen EH, Wijns W, Garcia-Garcia H, Waksman R

July 20, 2017 | 10.4244/EIJ-D-17-00254

Interventions for valvular disease

The interaction of de novo and pre-existing aortic regurgitation after TAVI: insights from a new quantitative aortographic technique

Tateishi H, Abdelghani M, Cavalcante R, Miyazaki Y, Campos C, Collet C, Slots T, Leite R, Mangione J, Abizaid A, Soliman O, Spitzer E, Onuma Y, Serruys P, Lemos P, de Brito Jr F

May 15, 2017 | 10.4244/EIJ-D-16-00647

Coronary interventions

Pressure-mediated versus pharmacologic treatment of radial artery spasm during cardiac catheterisation: a randomised pilot study

Collet C, Corral J, Cavalcante R, Tateishi H, Belzarez O, Costa J, Costa R, Chamié D, Onuma Y, de Winter R, Abizaid A, Serruys P

April 7, 2017 | 10.4244/EIJ-D-16-00868

Coronary interventions

DESyne novolimus-eluting coronary stent is superior to Endeavor zotarolimus-eluting coronary stent at five-year follow-up: final results of the multicentre EXCELLA II randomised controlled trial

Iqbal J, Verheye S, Abizaid A, Ormiston J, De Vries T, Morrison L, Toyloy S, Fitzgerald P, Windecker S, Serruys P

December 9, 2016 | 10.4244/EIJY15M10_04

Coronary interventions

One-year clinical outcomes of patients treated with everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a propensity score comparison of patients enrolled in the ABSORB EXTEND and SPIRIT trials

Costa Jr J, Abizaid A, Bartorelli A, Whitbourn R, Jepson N, Perin M, Steinwender C, Stuteville M, Ediebah D, Sudhir K, Serruys P

November 20, 2016 | 10.4244/EIJV12I10A206

Impact of post-dilation on the acute and one-year clinical outcomes of a large cohort of patients treated solely with the Absorb Bioresorbable Vascular Scaffold

Costa Jr J, Abizaid A, Bartorelli A, Whitbourn R, van Geuns R, Chevalier B, Perin M, Seth A, Botelho R, Serruys P

June 19, 2015 | 10.4244/EIJY15M05_06

Coronary interventions

The ABS mother-daughter platforms

Khorsandi M, Abizaid A, Dani S, Bourang H, Costa R, Kar S, Makkar R

May 19, 2015 | 10.4244/EIJV11SVA36

First-in-man assessment of the InSeal VCD, a novel closure device for large puncture accesses

Kambara A, Bastos Metzger P, Costa Jr J, Moreira S, Penner A, Sousa A, Sousa J, Grube E, Abizaid A

April 20, 2015 | 10.4244/EIJV10I12A242

The ABSORB EXTEND study: preliminary report of the twelve-month clinical outcomes in the first 512 patients enrolled

Abizaid A, Costa Jr J, Bartorelli A, Whitbourn R, van Geuns R, Chevalier B, Patel T, Seth A, Stuteville M, Dorange C, Cheong W-F, Sudhir K, Serruys P

April 20, 2015 | 10.4244/EIJV10I12A243

Latest news

New issue

Discover the Special Edition on valvular heart disease prepared by the course directors of PCR London Valves

(3D-TEE model - Optimal implantation)

November 15, 2019

Free access

2019 – A leap year for valvular heart disease

(Course directors PCR London Valves 2019)

November 15, 2019

Free Access

New this week: Deep Learning, near-infrared spectroscopy and much more

November 12, 2019

Trials Book

New update! Discover 17 new trials

(The Trials book is supported by Biotronik)

October 29, 2019

Free access

Guidelines, consensus & position papers

April 9, 2019

Insight

The SYNTAX score on its way out or … towards artificial intelligence

November 1, 2019

Free access

Medical device regulation in Europe – what is changing and how can I become more involved?

October 18, 2019

Alexandre Abizaid

Latest news

Coronary

Valvular disease

Heart failure

Peripheral

Hypertension

Stroke